公开(公告)号：WO2015126922A2

公开(公告)日：2015-08-27

申请号：PCT/US2015/016349

申请日：2015-02-18

Applicant: STC. UNM

Inventor： TIMMINS, Graham ,  CHOI, Seong, Won ,  SILKS, Louis, Pete A.

IPC: G01N33/532

CPC classification number: G01N33/58 ,  A61K49/0004 ,  G01N33/5695 ,  G01N2333/35 ,  G01N2458/15 ,  G01N2800/52

Abstract: In one embodiment, the invention provides methods of identifying the sensitivity and resistance to therapeutic drug regimens in a subject who suffers from, or who is suspected of suffering from, a Mycobacterium infection, the method comprising administering (1) isotopically labeled Pretomanid and/or Delaminid, or (2) isotopically labeled ethionamide and/or prothionamide, or (3) isotopically labeled pyrazinamide, or (4) isotopically-labeled isoniazid to the subject and thereafter measuring levels in a subject-derived sample of one or more isotopically-labeled markers corresponding to Mycobacterium-actiwated drug metabolites or degradation products, wherein the absence of detectable levels of Mycobacterium-activated drug metabolites or degradation products indicates either that the subject does not suffer from a Mycobacterium infection or suffers from a Mycobacterium infection which is resistant to treatment with the administered drug regimen.

Abstract translation: 在一个实施方案中，本发明提供鉴定患有或疑似患有分枝杆菌感染的受试者的治疗药物方案的敏感性和抗性的方法，所述方法包括施用（1）同位素标记的假单胞菌素和/或 （2）同位素标记的乙硫氨酰胺和/或丙硫氨酰胺，或（3）同位素标记的吡嗪酰胺或（4）同位素标记的异烟肼，然后测定受试者衍生的样品中一种或多种同位素标记 对应于分枝杆菌活化的药物代谢物或降解产物的标记，其中不存在可检测水平的分枝杆菌激活的药物代谢物或降解产物表明受试者不患有分枝杆菌感染或遭受耐受治疗的分枝杆菌感染 与施用的药物方案。

公开(公告)号：WO2009025820A2

公开(公告)日：2009-02-26

申请号：PCT/US2008/009909

申请日：2008-08-20

Applicant: STC. UNM ,  TIMMINS, Graham ,  MASTER, Sharon ,  DERETIC, Vojo, P.

Inventor： TIMMINS, Graham ,  MASTER, Sharon ,  DERETIC, Vojo, P.

IPC: A61K31/4409 ,  A61K31/44 ,  A61K9/16

CPC classification number: C07D213/81 ,  A61K9/0019 ,  A61K9/0073 ,  A61K31/44 ,  A61K31/4409 ,  C07D213/83 ,  C07D213/86

Abstract: The present invention relates to the use of isotopically labeled derivatives of isoniazid, ethionamide and related compounds as effective therapy for the treatment of mycobacterial diseases, including Mycobacterium tuberculosis.

Abstract translation: 本发明涉及异烟肼，乙硫异烟胺和相关化合物的同位素标记衍生物在治疗分枝杆菌疾病（包括结核分枝杆菌）中的有效疗法。

公开(公告)号：WO2019113431A1

公开(公告)日：2019-06-13

申请号：PCT/US2018/064456

申请日：2018-12-07

Applicant: STC. UNM ,  TIMMINS, Graham ,  LIU, Ke Jian ,  PAN, Rong

Inventor： TIMMINS, Graham ,  LIU, Ke Jian ,  PAN, Rong

IPC: A61K31/395 ,  A61K31/409 ,  A61P9/10

Abstract: A pharmaceutical composition includes a ferrochelatase inhibitor and a pharmaceutically acceptable carrier. In another aspect, a method of treating a subject having, or a t risk of having, a hemorrhagic stroke generally includes administering to the subject a pharmaceutical composition that includes a ferrochelatase inhibitor in an amount effective to ameliorate at least one symptom or clinical sign of hemorrhagic stroke.

公开(公告)号：WO2017023407A2

公开(公告)日：2017-02-09

申请号：PCT/US2016/035289

申请日：2016-06-01

Applicant: STC. UNM ,  JOHNSON, Patrick ,  BRINKER, C., Jeffrey ,  CARNES, Eric ,  TIMMINS, Graham ,  MUTTIL, Pavan

Inventor： JOHNSON, Patrick ,  BRINKER, C., Jeffrey ,  CARNES, Eric ,  TIMMINS, Graham ,  MUTTIL, Pavan

CPC classification number: A61K9/0073 ,  A61K9/12 ,  A61K9/1271 ,  A61K9/1617 ,  A61K47/543 ,  C08L23/22

Abstract: This disclosure describes compositions, vaccine, and methods that involve a biocomposite material Generally, the biocomposite material includes a cell and a lipid-silica matrix at least partially encapsulating the cell. In some cases, the cell can be viable but not culturable (VBNC). In some cases, the lipid-silica matrix includes a dried sol and/or possesses ordered nanostructure.

Abstract translation: 本公开描述了涉及生物复合材料的组合物，疫苗和方法。通常，生物复合材料包括细胞和至少部分包封细胞的脂质 - 二氧化硅基质。 在某些情况下，细胞可以存活但不可培养（VBNC）。 在一些情况下，脂质 - 二氧化硅基质包括干燥的溶胶和/或具有有序的纳米结构。

公开(公告)号：WO2014039829A2

公开(公告)日：2014-03-13

申请号：PCT/US2013/058521

申请日：2013-09-06

Applicant: STC. UNM ,  TIMMINS, Graham ,  CHOI, Seong, Won

Inventor： TIMMINS, Graham ,  CHOI, Seong, Won

IPC: A61K31/4409 ,  A61P17/00 ,  A61P11/00

CPC classification number: A61K41/0052 ,  A61K31/4409